1-2 of 2
Michael Taylor
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors

Catherine Dietrich, Alec Trub, Antonio Ahn, Michael Taylor, Krutika Ambani, Keefe T. Chan, Kun-Hui Lu, Christabella A. Mahendra, Catherine Blyth, Rhiannon Coulson, Susanne Ramm, April C. Watt, Sunil Kumar Matsa, John Bisi, Jay Strum, Patrick Roberts, Shom Goel
Journal: Cancer Discovery
Cancer Discov (2023)
https://doi.org/10.1158/2159-8290.CD-23-0954
Published: 04 December 2023
View article titled, INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors
Open the PDF for INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors in another window
Includes: Supplementary data
Journal Articles

EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma

Benchun Miao, Zhenyu Ji, Li Tan, Michael Taylor, Jianming Zhang, Hwan Geun Choi, Dennie T. Frederick, Raj Kumar, Jennifer A. Wargo, Keith T. Flaherty, Nathanael S. Gray, Hensin Tsao
Journal: Cancer Discovery
Cancer Discov (2015) 5 (3): 274–287.
https://doi.org/10.1158/2159-8290.CD-14-0295
Published: 05 March 2015
View article titled, EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Open the PDF for EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma in another window
Includes: Supplementary data